|
Analog Devices in talks to buy Maxim Integrated for about $20B Fox BusinessAnalog Devices Near Deal to Buy Maxim for $17 Billion Yahoo! VoicesChip-maker Analog poised to buy rival Maxim Integrated for more than $17 billion MarketWatchEETimes - Analog Devices, Maxim, Said to Be on the Verge of a $20B Deal - EE TimesAnalog Devices nears $20bn deal for chip rival Maxim Financial Times
|
|
Chiefs' Travis Kelce interrupts Patrick Mahomes' interview with wet willy during ACC | NBC Sports NBC SportsWill Patrick Mahomes need six Super Bowls to pass Tom Brady as greatest NFL QB ever? | Get Up ESPNReport: Chiefs, Chris Jones have begun contract talks NBC Sports - NFLChiefs' Travis Kelce gave Patrick Mahomes a wet willy during national TV interview Kansas City StarReading the tea leaves on the Kansas City Chiefs quarterback moves Arrowhead Addict
|
|
 (Bloomberg) -- Chinese biotech company Beigene Ltd. plans to raise $2.1 billion in a direct offering of 145.8 million shares to fund drug research and market its treatments in the U.S. and China, said the Nasdaq-listed company on Monday.The shares will be priced at $14.23 each, equivalent to a price of $185 per American Depository Share -- 5.6% lower than its closing price on Friday. The offering is expected to close on or around July 15, said the company, whose shares are also traded in Hong Kong.Buyers in the share sale include investment firm Baker Bros. Advisors LP and American generics giant Amgen Inc., which last year had purchased a 20.5% stake in Beigene for $2.7 billion to jointly develop cancer therapies. China's New Cancer Drugs Are Much Cheaper Than U.S. RivalsThe share sale comes after the Beijing-based company's blood cancer therapy became the first Chinese cancer drug to receive approval from the U.S. Food and Drug Administration last November, positioning Beigene as one of the most promising Chinese biotech companies taking on the world's biggest pharmaceutical firms in medical innovation and scientific research.Investment into Chinese biotech startups is surging as the opening up of the Asian giant's $132 billion pharmaceutical market creates an unprecedented profit-making opportunity for health-care companies. The Amgen stake, one of the first major tie-ups between American and Chinese drugmakers, was widely seen as a vote of confidence in Beigene's pipeline.The company has received appro
|
|
Private Label